Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + mitomycin + vinblastine
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The combination of cisplatin, mitomycin (as mitomycin C), and vinblastine—commonly referred to as the MVP regimen—is a platinum-based chemotherapy protocol used primarily for the treatment of advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer. Each component has a distinct mechanism of action: - Cisplatin is a platinum-containing compound that forms DNA crosslinks, leading to apoptosis by inhibiting DNA synthesis and function. - Mitomycin C is an alkylating agent that also induces DNA crosslinking and inhibits DNA synthesis. - Vinblastine is a vinca alkaloid that disrupts microtubule formation during cell division, arresting cells in metaphase. This combination has demonstrated antitumor activity with moderate toxicity profiles. It offers symptom palliation in advanced NSCLC and has shown efficacy in metastatic breast cancer patients previously treated with anthracyclines or taxanes[1][2][4][5].
- Brand names
- MVP
- Other names
- mitomycin C + vinblastine + cisplatinMVP regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cisplatin + mitomycin + vinblastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + mitomycin + vinblastine.